Pure Global AI
NCT06410300Recruiting

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

A Multi-Center Pilot Biomarker Study With Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Bo LuClinicalTrials.govradiation
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
Curative Radiotherapy
Study type
Observational
Intervention type
radiation
Sponsor & location
Primary sponsor
Bo Lu
Funder
University of Missouri-Columbia
Location
Columbia,New Brunswick,Rochester, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 19, 2024
End date
Apr 19, 2030
Enrollment
125 participants
Primary outcome

Clinical cardiopulmonary toxicities

Summary

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with
 lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and
 immunotherapy through timed monitoring and blood sample collection and to identify
 correlative biomarkers for predicting cardiopulmonary adverse events.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06410300
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06410300 through Pure Global AI's free database. This phase not specified trial is sponsored by Bo Lu and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 125 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.